Partnered With Chinese Pharmaceutical Enterprise Association
Access to Over 300 Big Chinese Pharmaceutical Companies
|
Shifield International Group is a global pharmaceutical Business development company with an innovative business model that provides a financially advantageous and creative approach to drug development. Shifield’s unique partnering model pairs strategic funding and experienced clinical development resources with late phase drug development candidates across multiple indications. The result is accelerated portfolio expansion with minimal financial risk.
|
|
Shifield will invest on Phase II and Phase III clinical study of the target compound, and will take all financial response to get the phase II/ III study done. Shifield only charge when the phase III study is approved. Shifield recognizes that each of our current and future Pharma Partners have distinct needs and requirements. As such, Shifield needs to understand each partner's specific funding, legal and operational needs and will develop a co-development, licensing, or purchase framework that is specifically tailored to the Pharma Partner’s needs.
|
